Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke

Summary

An open-label, blinded endpoint, randomized controlled trial that includes patients diagnosed with non-disabling, non-large vessel occlusion, acute minor stroke within 4.5 hours of onset. Eligible participants would be randomly assigned to the thrombolysis group (intravenous alteplase) and the dual antiplatelet group (oral aspirin plus clopidogrel). The primary outcome is the proportion of the excellent functional outcome (modified Rankin scale 0-1) at 90 days.

Timeline

Start

2023-07

Primary completion

2027-07

Completion

2027-07

Drugs

Indications